This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Albireo Pharma Gestion
Gestion contrôle des critères 2/4
Informations clés
Ron Cooper
Directeur général
US$6.0m
Rémunération totale
| Pourcentage du salaire du PDG | 9.8% |
| Durée du mandat du directeur général | 7.7yrs |
| Propriété du PDG | 0.2% |
| Durée moyenne d'occupation des postes de direction | 4.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 5.5yrs |
Mises à jour récentes de la gestion
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2022 | n/a | n/a | -US$131m |
| Jun 30 2022 | n/a | n/a | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$33m |
| Dec 31 2021 | US$6m | US$590k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$48m |
| Jun 30 2021 | n/a | n/a | -US$136m |
| Mar 31 2021 | n/a | n/a | -US$120m |
| Dec 31 2020 | US$3m | US$570k | -US$108m |
| Sep 30 2020 | n/a | n/a | -US$90m |
| Jun 30 2020 | n/a | n/a | -US$82m |
| Mar 31 2020 | n/a | n/a | -US$78m |
| Dec 31 2019 | US$3m | US$551k | -US$63m |
| Sep 30 2019 | n/a | n/a | -US$71m |
| Jun 30 2019 | n/a | n/a | -US$63m |
| Mar 31 2019 | n/a | n/a | -US$61m |
| Dec 31 2018 | US$4m | US$530k | -US$46m |
| Sep 30 2018 | n/a | n/a | -US$35m |
| Jun 30 2018 | n/a | n/a | -US$28m |
| Mar 31 2018 | n/a | n/a | -US$19m |
| Dec 31 2017 | US$2m | US$460k | -US$24m |
| Sep 30 2017 | n/a | n/a | -US$31m |
| Jun 30 2017 | n/a | n/a | -US$28m |
| Mar 31 2017 | n/a | n/a | -US$20m |
| Dec 31 2016 | US$4m | US$400k | -US$16m |
Rémunération vs marché: Ron's total compensation ($USD6.04M) is above average for companies of similar size in the US market ($USD3.58M).
Rémunération et revenus: Ron's compensation has increased whilst the company is unprofitable.
PDG
Ron Cooper (59 yo)
7.7yrs
Titularisation
US$6,041,334
Compensation
Mr. Ronald H. W. Cooper, also known as Ron, serves as Independent Director at Generation Bio Co. since March 2021. He has been the Chief Executive Officer and President of Albireo Pharma Inc. since July 20...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 7.7yrs | US$6.04m | 0.16% $ 1.5m | |
| CFO & Treasurer | 4.4yrs | US$1.71m | 0.066% $ 606.6k | |
| Chief Regulatory Officer | 6.3yrs | US$1.73m | 0.018% $ 161.4k | |
| Co-Founder & VP of Development | no data | pas de données | pas de données | |
| Chief Scientific Officer | 15.2yrs | US$1.40m | 0.17% $ 1.6m | |
| Chief Technology Officer | 1.9yrs | pas de données | pas de données | |
| Chief Legal Officer | 4.8yrs | pas de données | 0.016% $ 145.5k | |
| Chief Human Resources Officer | 3.3yrs | pas de données | 0.027% $ 244.7k | |
| VP & Global Project Head | no data | pas de données | pas de données | |
| Chief Commercial Officer | 4yrs | US$1.96m | 0.11% $ 982.0k | |
| Chief Business Officer | 1.3yrs | pas de données | pas de données | |
| Chief Medical Officer | less than a year | pas de données | pas de données |
4.2yrs
Durée moyenne de l'emploi
58.5yo
Âge moyen
Gestion expérimentée: ALBO's management team is considered experienced (4.2 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 7.5yrs | US$6.04m | 0.16% $ 1.5m | |
| Independent Chairman of the Board | 15.1yrs | US$282.44k | 0.27% $ 2.5m | |
| Independent Director | 6.3yrs | US$266.82k | 0.14% $ 1.3m | |
| Independent Director | 7.4yrs | US$264.94k | 0.13% $ 1.2m | |
| Director | less than a year | pas de données | pas de données | |
| Independent Director | less than a year | pas de données | pas de données | |
| Independent Director | 4.8yrs | US$249.94k | 0.14% $ 1.3m | |
| Director | less than a year | pas de données | pas de données |
5.5yrs
Durée moyenne de l'emploi
59yo
Âge moyen
Conseil d'administration expérimenté: ALBO's board of directors are considered experienced (5.5 years average tenure).